Geriatric
A new study found that more than one-third of patients aged older than 65 years do not receive...
Treosulfan demonstrated a significant improvement in EFS over RIC busulfan with a clinically meaningful benefit.
The approval was based on data from a trial that randomized patients with newly-diagnosed IDH1-mutated AML.
Advertisement
Ibrutinib and venetoclax demonstrated superior MRD responses in older/unfit patients with previously untreated CLL.
Older patients are at a significantly increased risk of immune-related AEs.
Researchers evaluated the effectiveness of a personalized sequential therapy for older patients with multiple myeloma.
Advertisement
The use of hematopoietic stem cell transplantation (AHCT) is associated with excellent 2-year outcomes in multiple myeloma ...
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.